School of Pharmacy, Jiangsu University, Zhenjiang 212013, Jiangsu, China.
J Nanosci Nanotechnol. 2021 May 1;21(5):3035-3040. doi: 10.1166/jnn.2021.19139.
The development of novel sonosensitizers with safety and efficiency is a key problem in anti-tumor sonodynamic therapy. Phycocyanin (PC) has been proved to have the singlet oxygen radicals (ROS) generation ability, and the potential of PC as a novel sonosensitizer has been investigated. To overcome the disadvantages of PC , such as poor stability and low half-life, PC nanoparticles (PCNP) were prepared by the cross-linking method. According to the results, PCNP has been found with good morphology, good particle size distribution and good stability. Human breast cancer cell line MCF-7 was used to investigate PCNP cell uptake ability. ROS generation and cytotoxicity under ultrasonic irradiation (sonotoxicity) were also studied on this cell. Under the condition of 0.75 w/cm² ultrasound, PCNP has a good ROS productivity and is equivalent to the sonotoxicity of the known sonosensitizer hematoporphyrin monomethyl Ether (HMME). In conclusion, PCNP is expected to be developed as an effective sonosensitizer for the sonodynamic therapy of tumors.
新型声敏剂的研发是肿瘤声动力学治疗的关键问题，安全性和有效性是关键。藻蓝蛋白（PC）已被证明具有生成单线态氧（ROS）的能力，其作为新型声敏剂的潜力已被研究。为了克服 PC 稳定性差和半衰期短等缺点，采用交联法制备了藻蓝蛋白纳米颗粒（PCNP）。结果表明，PCNP 具有良好的形态、良好的粒径分布和良好的稳定性。利用人乳腺癌细胞 MCF-7 研究了 PCNP 的细胞摄取能力，并在超声辐照下（声毒性）研究了 ROS 的生成和细胞毒性。在 0.75 w/cm²超声条件下，PCNP 具有良好的 ROS 生成能力，与已知声敏剂血卟啉单甲醚（HMME）的声毒性相当。总之，PCNP 有望成为肿瘤声动力学治疗的有效声敏剂。
